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Abstract
Objective: To identify the risk-predictive baseline profile patterns of demographic, genetic, immunologic, and metabolic
markers and synthesize these patterns for risk prediction.
Research Design and Methods: RuleFit is used to identify the risk-predictive baseline profile patterns of demographic,
immunologic, and metabolic markers, using 356 subjects who were randomized into the control arm of the prospective
Diabetes Prevention Trial-Type 1 (DPT-1) study. A novel latent trait model is developed to synthesize these baseline profile
patterns for disease risk prediction. The primary outcome was Type 1 Diabetes (T1D) onset.
Results: We identified ten baseline profile patterns that were significantly predictive to the disease onset. Using these ten
baseline profile patterns, a risk prediction model was built based on the latent trait model, which produced superior
prediction performance over existing risk score models for T1D.
Conclusion: Our results demonstrated that the underlying disease progression process of T1D can be detected through
some risk-predictive patterns of demographic, immunologic, and metabolic markers. A synthesis of these patterns provided
accurate prediction of disease onset, leading to more cost-effective design of prevention trials of T1D in the future.
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Introduction
Type1 Diabetes (T1D) is an autoimmune disorder that has a
diverse pathogenesis, clinical phenotype, and outcome [1]. It is
associated with a progressive immune-mediated loss of insulin-
secreting islet cells, leaving a trail marked by characteristic
immunologic and metabolic signs that provide predictive markers
of disease [2], such as the 2 hour glucose and C-peptide markers.
The increasing understanding of the immune pathogenesis of T1D
has led to the possibility that preventive interventions could delay
or prevent its occurrence. Some prevention trials, such as the
European Nicotinamide Diabetes Intervention Trial and the
Diabetes Prevention Trial-Type 1 (DPT-1), have been launched to
test interventions in individuals with autoimmune pre-diabetes [3–
5]. They have shown that individuals with certain degree of risk
can be recruited through the assessment of relatives of T1D
patients by autoantibody and metabolic testing.
Despite the possibility of predicting T1D on the basis of genetic,
immunologic, and metabolic markers [2,6–8], there are still a
substantial proportion of those classified as high risk who do not
progress to clinical diabetes within five years of detection.
Therefore, a number of studies have been conducted to refine
the prediction of T1D to improve accuracy and efficiency, by
developing risk score models using all the potential risk markers
[6–8]. For example, a risk score is developed in [6], which was
shown to be helpful for the prediction of T1D in relatives of
patients who are autoantibody-positive. The Cox proportional
hazards regression model (CPH) has been the most commonly
used model in the past. The CPH model is appealing due to its
mathematical simplicity and computational convenience, in which
the baseline survival function does not need to be modeled
explicitly in the model training. However, the CPH model was
essentially designed to measure the effects of covariates on
changing the hazard function but not modeling individual patient
risk. In other words, the CPH model is not suitable to predict an
individual’s risk since the hazard function is incomplete without
the baseline survival function. Although it is possible to fit a non-
parametric baseline survival function after the CPH model is
trained on data, its applicability is still limited by its proportional
hazards assumption. As a result, existing risk-scores models [6–8]
are only capable of stratifying subjects into different risk levels,
rather than assessing individual’s risk and predicting the disease
onset.
The difficulty in developing a risk score model comes from the
heterogeneity of T1D and the complex interplay among diverse
risk factors. It is known that within the same genetically
predisposed children, pre-diabetic subjects may have very
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heterogeneous characteristics with regards to the expected rates of
seroconversion to islet autoantibody positivity as well as diagnosis
of T1D [9]. Existing research on T1D risk model development has
shown that a combination of multiple markers may produce high
predictive accuracy for early disease prediction [6–8,10].
In this paper, we seek to explore whether genetic, immunologic,
and metabolic markers tend to occur in a predictable pattern that
might be captured by statistical analysis and could therefore be
used to dissect out individual’s disease risk. We use the powerful
rule-discovery algorithm, the RuleFit [11], to systematically
explore the possible risk-predictive baseline profile patterns,
defined as ‘‘rules’’. Then, we develop a novel latent trait model
to model the association of the rules with the underlying disease
risk and further link the disease risk with the clinical outcome,
forming the basis for risk estimation and outcome prediction. Our
main contributions are: 1) we have identified novel and
meaningful risk-predictive rules from the DPT-1 participants,
which may lead to a better understanding of disease progression
and high prediction accuracy for T1D; 2) we have developed a
novel latent trait model which is capable of synthesizing the rules
for prognosis, and, by extracting the item information curves (IIC)
from the latent trait model, it is also possible to investigate the
distribution of prognostic power of each rule over the spectrum of
disease severity, revealing which marker measurements produce
superior prognostics for a given cohort. Such a prognostic model
with consideration of baseline profile patterns that involve
interactions between markers, will enable more homogeneous risk
grouping as well as identification of intermediate checkpoints and
surrogate end points, which may lead to novel cost-effective
screening strategies for future clinical trial design in preventing
T1D.
Methods
1. Data
The Diabetes Prevention Trial-Type 1 (DPT-1) was one of the
largest randomized, prospective studies in North America from
1995 to 2003, with the objective to determine if T1D can be
prevented or delayed by a preclinical intervention of oral insulin
intake or low-dose insulin injections. The DPT-1 consists of two
separate trials, one of oral insulin (to induce oral tolerance) and the
other of parenteral insulin with daily subcutaneous low-dose
insulin and annual intravenous insulin. A total of 103,391 first-
and second-degree non-diabetic relatives of individuals were
screened for ICA-positive subjects. The 3,483 relatives positive
for islet-cell antibodies (ICA) were then staged to quantify the
projected five-year risk of diabetes [12]. Of those, 372 subjects
whose five-year risk was considered to be 25% to 50% with normal
oral glucose tolerance test (OGTT) were entered into the oral
insulin trial; 339 subjects whose five-year risk was considered to be
50% to 70% with abnormal OGTT or loss of FPIR to an
intravenous glucose tolerance test (IVGTT) were entered into the
parenteral trial. The criteria for eligibility can be found in [12]. All
subjects (and/or their parents) signed a written consent form
approved by the participating study center’s human subjects
committee.
To study the natural history of the disease, only the subjects who
were randomized to the control arms of the studies were used in
this analysis (186 from oral trial placebo arm and 170 from
parenteral trial observation arm). We plan to focus on demo-
graphic, immunologic, and metabolic markers. Specifically, we
will use the titer values for different autoantibodies for assessment,
including ICA, IAA, GAD, ICA512, and MIAA (micro-insulin
autoantibodies). For metabolic indices, we have fasting glucose,
glycated hemoglobin (HbA1c), fasting insulin, first-phase insulin
response (FPIR) from IVGTTs, and Homeostasis model assess-
ment of insulin resistance (HOMA-IR). From OGTTs, in addition
to 2-hour glucose and fasting glucose, we have collected blood
samples for C-peptide measurements in the fasting state and then
30, 60, 90, and 120 minutes after oral glucose. We also have
computed peak C-peptide as the maximum point of all measure-
ments and AUC (area under curve) C-peptide using the trapezoid
rule. Furthermore, we also include age and Body Mass Index
(BMI), which have been typically included as covariates in most of
the existing risk models for T1D. The baseline statistics of the
study subjects are presented in Table 1.
2. Statistical methods
Let X~½X1,X2,:::,Xpdenotes the p pvariables corresponding to
candidate risk markers introduced in Section 2.1. Our hypothesis
is that there are unknown baseline profile patterns, indicating risk
levels for individuals, which can be characterized as rules over
these markers. As these baseline profile patterns are largely
unknown and a risk estimation mechanism using these patterns is
also lacking, in this paper, we propose an integrated framework of
an existing rule-discovery algorithm, the RuleFit [11] and a novel
latent trait model that will be developed in this paper, to fill in
these gaps. Specifically, the rule-discovery algorithm can be used
to discover the hidden rules that may be predictive to the disease
risk. The latent trait model will be used to model the associations
between the identified rules with the underlying disease risk and
further estimate individual disease risk by probabilistic inference,
based on these associations.
2.1. Rule discovery by RuleFit. We use rules to define the
baseline profile patterns, sincerules can be easily interpreted, easily
handle heterogeneity and complex interaction between markers.
Essentially, a rule defines the abnormal range of some markers.
With the presence of an abnormality, the disease risk increases.
Thus, a comprehensive set of risk-predictive rules act as a set of
sensors dispersed over the whole course of disease progression,
providing us the evidences for risk estimation by looking into each
individual’s profile of abnormalities. On the other hand, this set of
rules for characterizing T1D progression is currently lacking, as
the etiology of T1D is still not fully understood [13]. As traditional
epidemiology studies mostly focus on studying hypotheses regard-
ing individual risk factors, knowledge about the heterogeneity and
complex interplay between risk factors that are crucial on defining
the rules remains largely unknown.
We use RuleFit[11] to discover the hidden rules that may be
predictive of the disease risk. RuleFit is a high-dimensional
computational algorithm for rule discovery, which is capable of
exhaustively searching for potential rules on a large number of
candidate risk markers. It has two phases, the ‘‘rule generation
phase’’ and ‘‘rule pruning phase’’: 1) Rule generation: At this
stage, random forest [14] is used to exhaustively search for
candidate rules over the potential risk factors. Random forest is a
high-dimensional rule discovery approach that extends traditional
decision tree models. Specifically, a random forest estimates a
number of trees, with each tree being estimated on a relatively
homogenous subpopulation generated by bootstrapping the
original dataset. Since each tree employs a set of rules to
characterize a subpopulation, the random forest is actually a
comprehensive collection of rules that are able to characterize the
whole dataset. On the other hand, as a heuristic and exhaustive
search approach, the random forest may produce a large number
of less-predictive or redundant rules, which requires the following
second step to refine the learning results. 2) Rule pruning: As the
random forest will generate many rules that can be redundant or
A Rule-Based Prognostic Model for Type 1 Diabetes
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Table 1. Baseline statistics of the study subjects.
Oral Insulin Trial N=186 Parenteral Insulin Trial N=170
IDDM (%) 53(28%) 70(41%)
Age -year (mean) 12.30(8.60) 15.34(9.92)
BMI Z-score (median) * 20.90(22.3520.38) 21.48(23.0420.01)
Race n(%)
White 163(89.07%) 128(95.18%)
African American 2(1.09%) 1(0.60%)
Hispanic 14(7.65%) 5(3.01%)
Other 7(3.76%) 6(3.53%)
Gender n(%)
Male 105(56.45%) 89(52.35%)
Female 81(43.55%) 81(47.65%)
Relationship to patient w/diabetes n(%)
Sibling 108(58.06%) 113(66.47%)
Offspring 53(28.49%) 39(22.94%)
Parent 7(3.76%) 5(2.94%)
Second Degree 18(9.68%) 13(7.65%)
HLA genotype:
Priamryhaptype
0101/0501 27(14.59) 14(8.24)
0102/0604 10(5.41%) 16(9.41%)
0201/0201 12(6.49%) 10(5.88%)
0301/0301 19(10.27%) 11(6.47%)
0301/0302 77(41.62%) 75(44.12%)
0501/0201 16(8.65%) 17(10.00%)
Other 25(13.44%) 10(5.88%)
Secondayhaptype
0301/0301 8(4.32%) 12(7.06)
0301/0302 71(38.38%) 45(26.47%)
0501/0201 69(37.30%) 81(47.65%)
0501/0301 15(8.11) 15(8.82)
Other 23(12.37%) 17(10.00%)
Immunological factors:
ICA titer (JDF Units**) (median) 80.00(40.00–160.00) 160.00(40.00–320.00)
IAA titer (nU/ml) (median) 192.30(83.30–435.70) 109.25(26.70–295.34)
ICA512 (median) 0.033(0.006–0.677) 0.081(0.003–0.645)
GAD65(median) 0.204(0.027–0.677) 0.322(0.024–0.738)
Metabolic factors:
Fasting Glucose (mmol/L)- IVGTT 4.84(0.51) 4.94(0.49)
Fasting Insulin (mU/L)-IVGTT 15.41(9.68) 12.01(7.76)
FPIR (ul/ml)-IVGTT 158.88(99.16) 72.80(37.10)
HOMA-R-IVGTT 3.39(2.35) 2.69(1.84)
FPIR/HOMA-R-IVGTT 55.64(33.13) 32.90(17.09)
Fasting Glucose (mg/dL)-OGTT 86.20(7.78) 89.22(9.58)
Two-hour Glucose (mg/dL)-OGTT 105.74(19.57) 122.28(31.59)
Peak C-Peptide (nmol/L)-OGTT 5.44(2.19) 4.84(1.97)
AUC C-Peptide(nmol/L)-OGTT 508.70(205.79) 439.28(174.03)
HBA1C 5.33(0.34) 5.38(0.50)
Note: Data are mean (6 SD), n (%), or median (Inter-quartile range).
*BMI Z-score from 2000 CDC Growth chart.
**JDF denotes Juvenile Diabetes Foundation.
doi:10.1371/journal.pone.0091095.t001
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irrelevant to early withdrawal due to overfitting, the sparse
regression model [11,15] will be applied to select a minimum set of
risk-predictive rules, by using all the potential rules as predictors
and the withdrawal status as the outcome. The sparse regression
model is a high-dimensional variable selection model [11,15].
Considering each rule as a ‘‘variable’’, rule pruning is essentially a
variable selection problem. This problem is to selecting a subset of
rules out of a pool of qcandidate rules, denoted as
R~ R1,R2, . . . ,Rq
 
, which are predictive to the output variable
Y. This problem is particularly challenging in high-dimensional
settings where qis large. Recently, the Least Absolute Shrinkage
Selection Operator (LASSO) is proposed [15], which is a sparse linear
regression model that is capable to identify a subset of relevant
variables out of a huge list of candidate variables. Specifically, the
formulation of LASSO is
min
b
jjY{Rbjj22zljjbjj1
Here, the square error term,jjY{Rbjj22, is used to measure the
model fit. The L1-norm penalty termjjbjj1, defined as the sum of
the absolute values of all elements in b, is used to measure the
complexity of the regression model. The user-specified penalty
parameter,l, aims to achieve an optimal balance between the
model fitness and model complexity – largerlwill result in sparser
estimate for b. Efficient algorithms have been developed to solve
the optimization problem [11,15]. In our study, since the output
variable Y, i.e., the withdrawal status, is a binary variable, the
sparse logistic regression [15] is a better choice than linear
regression, which can be readily implemented in the R package of
RuleFit [15]. More details on RuleFit can be found in [15].
In a summary, RuleFit is computationally efficient since efficient
algorithms have been developed for both Random Forest and
sparse linear regression models. Since it is an integration of
random forest and LASSO, it has several important parameters to
be specified, including the number of trees, the complexity of the
trees that is controlled by the average number of terminal nodes,
and the penalty parameterl. According to the extensive simulation
studies performed in [15], the default parameters values for the
number of trees and the average number of terminal nodes are
333 and 4, respectively. We obtained the optimal values of these
three parameters using the automated cross-validation procedure
in Rulefit in a manner of grid search, which are close to these
default values, e.g., the number of trees and the average number of
terminal nodes are 250 and 4.5, respectively. In our experiments,
we have found that the RuleFit is robust to the specification of
these parameters.
2.2. Latent trait model. Disease risk is a latent trait that is
not directly measureable. As we mentioned earlier, rules are
essentially measureable evidence that are associated with the
underlying disease risk. Specifically, as a rule defines the abnormal
range of some markers, the satisfaction of a rule corresponds to the
presence of an abnormality. It is known that some abnormalities
can most likely be observed at certain progression stages, which
provide us the possibility that we can infer the most possible
disease risk for each subject based on this individual’s profile of
abnormalities, if the associations between the abnormalities with
disease severity can be modeled. This statistical inference problem
bears a resemblance with the classic problem in psychometrics, the
inference of abilities, attitudes or personalities by gathering
evidence from questionnaire responses or tests, using the latent
trait theory.
As traditional latent trait models can only be used to estimate
the associations between the discovered rules with the underlying
disease severity, in this paper, we develop a novel latent trait model
which is not only capable of modeling these associations (as shown
in the box labeled with C1 in Fig. 1), but alsopredicting the disease
onset (as shown in the box labeled with C2 in Fig. 1). With these
associations, the likelihood of endorsement of each rule can be
calculated and the latent trait model will further capitalize on these
likelihoods to infer the underlying disease severity and predict the
disease onset.
To model the association between the disease severity with
disease onset, the latent trait model assumes that the probability of
an individual’s endorsement of a rule is a function of both the
individual’s (latent) disease severity and the association between
this rule and the disease severity, which corresponds to the
information about where the rule stands in the disease severity
continuum and how predictive the rule is. In practice, this
relationship is modeled by a monotonically increasing function
called the item characteristic curve (ICC). For example, the two-
parameter logistic model (2PL) can be specified for rule Rl as
follows:
log
Pl(Rl~1jh)
Pl(Rl~0jh)~al(h{bl)
Here,Pl Rl~1jhð Þon the left hand side is the probability of an
endorsement of the ruleRl , given the (latent) disease severityh. On
the right side, bl is the item difficulty parameter for rule Rl that
determines the position of the ICC in relation to the disease
severity scale. The item difficulty is the disease severity level
required to achieve a 50% change of an endorsement,
i.e.,Pl Rl~1jh~blð Þ~Pl Rl~0jh~blð Þ~0:5. As bl increases,
the item becomes more useful to identify subjects with higher
disease severity. For example, if a subject endorses a symptom,
Rl~1, that has a large bl , then it is unlikely that the disease
severity his small, since hvblmeansPl Rl~1jh~blð Þv0:5. The
smallerh, the smaller probability of observing Rl~1, which
contradicts with the data. The remaining parameter, al , is the
item discrimination for ruleRl , which determines the amount of
change in the log odds, Pl Rl~1jhð Þ=Pl Rl~0jhð Þ, for one unit of
change in the disease severity. Thus, a larger almeans that the rule
is more sensitive to small changes in the disease severity,
discriminates more clearly among the subjects, and hence is more
informative and reliable. Throughout this paper, we use this two-
parameter item response function due to its flexibility and
interpretability. We also would like to point out that our
Figure 1. Latent trait model for rule synthesis.
doi:10.1371/journal.pone.0091095.g001
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methodology is generic and can be extended to other item
response functions when needed.
It is worthy of mentioning that, the item information curve (IIC)
can be extracted from the ICC, which reflects how much
information a rule may have on measuring the underlying disease
severity [16]. This can be achieved through the derivation of the
fisher information from the 2PL model, as the fisher information
reflects the information about an unknown parameter [16]. The
IIC for the 2PL model is:
I(h)~
(p0(h))2
p(h)½1{p(h)0
,
wherep hð Þ~Pl Rl~1jhð Þ and p0(h) denotes the first derivative
of p(h)with respect toh.
Another task is to model the association between the disease
severity with disease onset, i.e., as denoted as Y~F h,Zð Þ in C2 of
Fig. 1, where Ydenotes the disease onset, his the disease severity,
and Z1, . . . ,Zt{1f gdenote some other potential predictors which
may provide useful supplementary information besides the rules.
We can use the logistic regression model.E.g.,
P Y~1ð Þ~ 1
1ze{ c1Z1z...zct{1Zt{1zcthið Þ
.
For instance, one exemplary predictor that can be included in
Z1, . . . ,Zt{1f g is the clinician’s subject assessment of the subject’s
disease risk, which may provide valuable baseline assessment.
We have developed a MCMC (Markov Chain Monte Carlo)
algorithm for the model parameter estimation for this latent
variable model. Denote all the parameters as
g~ a1, . . . ,aL,b1, . . . ,bL,h1, . . . ,hn,c1, . . . ,ctf g and D as the whole
dataset that includes all the individual’s measurements
on Y ,R1, . . . ,RL,Z1, . . . ,Zt{1f g. We estimate the unknown pa-
rameters gby maximizing its posterior distribution,P gjDð Þ, whose
explicit expression can be found in the Appendix S1. The MCMC
algorithm provides a computational method to estimate the
posterior distribution, P gjDð Þ, which is a description of the
probabilities of possible values for ggiven the observed data. The
MCMC algorithm is actually a sampling algorithm which draws
samples fromP gjDð Þ. Point estimates of the parameters,g, can
then be obtained using statistics, e.g., mean and mode, of the
posterior samples ofg. A detailed implementation procedure is
given in the Appendix S1.
Results
1. Identified risk-predictive rules on the DPT-1 population
RuleFit has been applied on the previously described DPT-1
dataset to derive a set of risk-predictive rules. There is no need to
standardize or transform the original dataset, since RuleFit uses
random forest to generate the rules, which is able to handle dataset
where variables have different scales. It also has an established
procedure that adapts to missing data by use of surrogate
measures. Specifically, we use the baseline characteristics in
DPT-1, focusing on immunologic and metabolic markers. As
shown in Section 2.1, these markers include ICA, IAA, GAD, ICA
512, MIAA, fasting glucose, HbA1c, fasting insulin, first-phase
insulin response (FPIR), Homeostasis model assessment of insulin
resistance (HOMA-IR), and 2 hr glucose, fasting glucose, C-
Peptide measurements. We have computed peak C-peptide as the
maximum point of all measurements, the timing of this peak C-
peptide, the early C-peptide response (30-0 min C-peptide
difference) and AUC (area under curve) C-peptide using the
trapezoid rule. In addition, we also include age, gender and Body
Mass Index (BMI) into our model. Rules are derived on these
markers by running RuleFit. By tuning the parameters using cross-
validation as suggested in [11], the significant rules identified by
the RuleFit model are shown in Table 2. Note that the support of a
rule is the proportion of the subjects in the cohort who endorse this
rule.
2. Validation of the identified rules by survival analysis
As each derived rule defines two groups, one satisfying the rule
and the other one not, survival analysis can be applied to evaluate
the separation of these two groups. Therefore, to test the
prognostic values of these ten rules, we have performed the
Kaplan-Meier survival analysis on the same 356 subjects for each
of the top 10 rules. The results are shown in Fig. 2. In each plot,
the solid curve represents the survival curve together with their
95% confidence intervals of the group for which the rule is not
endorsed. The dotted curve represents the group for which the
rule is endorsed. We show the p-value(i.e., logrank test) of the
group separation of each rule in Table 3. It is apparent that all the
rules are significant based on both Kaplan-Meier analysis and
logrank test.
3. Modeling the associations between the rules with the
underlying disease risk
We have implemented the MCMC algorithm described in the
Appendix S1 to fit the parameters of the item response functions in
WINBUGS [17]. We draw N=25000 samples and discard the
initial 5000 samples generated by the MCMC algorithm for
warming-up[17]. Convergence of the MCMC algorithm is
checked according to the guidance provided in [17], e.g., by
comparing the samples obtained from several runs. The means of
the posterior samples of g are used as the parameter estimations.
With the estimated a1, . . . ,aL,b1, . . . ,bL, the curves of the fitted
item response functions can be obtained, which are shown in
Fig. 3. We also report the information curves of the rules in Fig. 4,
which reveal information about within which segment of the
disease risk continuum the rules are most discriminant. From
Fig. 3, it can be seen that there are two kinds of rules, one is ‘‘risk-
increasing’’ as the satisfaction of the rules increases the disease risk;
the other one is ‘‘risk-decreasing’’ as the satisfaction of the rules
decreases disease risk. It is also clear that the relationship between
the rules with disease risk is very different. For example, it can be
seen from Fig. 3 that, when disease risk is low to moderate, rules 4
and 5 are likely to be satisfied. On the contrary, rule 6 is not very
likely to be satisfied until the disease risk is high. This implies that if
a subject endorses rule 6, it is very likely the disease risk is high.
The item information curve of rule 6 in Fig. 4 also demonstrates
that rule 6 is the most informative item on the high-risk segment of
the disease risk continuum. We also observe that the item response
functions of some rules are very similar, such as rule 4 with rule 5,
rule 8 and rule 10.
4. Assessment of the prediction accuracy of the proposed
rule-based method
As mentioned in previous sections, unlike existing risk score
models [6–8] that are only capable of stratifying subjects into
different risk levels, our proposed rule-based prognostic method
A Rule-Based Prognostic Model for Type 1 Diabetes
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can assess individual’s risk and predict the disease onset. Thus, it is
of interest to investigate the risk prediction ability of the proposed
latent trait method. We use an 80/20 validation procedure to
evaluate the performance. Within this cross-validation procedure,
the data is randomly divided into a training set (with 80% of the
whole samples) and a testing set (with 20% of the whole samples).
Rather than using the 10 rules (listed in Table 2) that have been
identified on the whole dataset to fit the prediction model, here, to
avoid overstatement of the prediction performance, we use RuleFit
on the training set to identify the rules. Afterward, again, the latent
trait theory is applied to these rules, fitted on the training data and
gives classification accuracy on the testing data. Since at this stage,
we don’t have prior knowledge on which covariates should be
included as Z1, . . . ,Zt{1f gin the classification model, we only use
the latent disease severity h as the predictor. This 80/20 validation
procedure is repeated 100 times and 100 pairs of AUC values can
be obtained. The average area under curve (AUC) value is 0.82.
For comparison, we also have applied the decision tree, random
forest, logistic regression, SVM (Support Vector Machine)with
linear kernel, Gaussian kernel, polynomial kernel, on the original
variables, but the average AUCs are only 0.71, 0.74, 0.62, 0.67,
0.65, 0.58, respectively. Note that the parameters used in these
models are tuned according to the standard 10-fold cross
validation procedure with a grid search. For example, in tuning
the parameters of the SVM with linear kernel, the only parameter
is the soft margin parameter, while the parameters of the SVM
with Gaussian kernel has one more parameter, the kernel
parameter. In the search of the best combination of the kernel
parameter and the soft margin parameter, a grid search with
exponentially growing sequences is usually used, e.g., in our
case, 2{5,2{3, . . . ,25,27,29
 
andf2{15,2{13,:::,23,25,27gfor the
two parameters, respectively. Each combination of the parameter
choices is evaluated using the 10-fold cross validation procedure,
and the combination with the best cross-validation accuracy is
picked. All the models for comparison are implemented using the
routines in MATLAB.
We’d like to mention that the rules identified by the Rulefit in
the training datasets are quite consistent with the 10 rules listed in
Table 2. All of them frequently appear in the selected rules on
each training dataset, while only small variations on the cut-off
values are observed on some rules as shown in Table 2.
Furthermore, it is of interest to evaluate the effectiveness of the
proposed rule-based method on other datasets rather than the
DPT-1 baseline data. Six datasets (sonar, liver, pima, breast
cancer, appendicitis, heart) are chosen from the UCI machine
learning data repository that have similar dimensionality and
sample size as the DPT-1 baseline data. We also simulate a dataset
using the following strategy: First, we fit a latent trait model of the
ten rules (as shown in Table 2) using all the samples in the DPT-1
dataset. Then, we randomly generate samples from this latent trait
model, i.e., by randomly generating the values of the ten rules and
then generating the value of the disease onset using the
probabilistic relationships between the rules with the disease
onset. Note that we generate the same number of samples as in the
DPT-1 dataset. Finally, the same 80/20 cross-validation proce-
dure is applied on each of the datasets including the six UCI
datasets and the simulated dataset. The prediction performances
(measured by the AUC values) of all the methods on all these
datasets are shown in Table 4, which clearly demonstrate that the
proposed rule-based method outperforms other competing algo-
rithms across all the datasets.
Discussion
The comprehensive baseline data from DPT-1 provides us the
opportunity to identify some predictable patterns from genetic,
immunologic, and metabolic markers, which can be used to
Table 2. The TOP 10 rules identified by RuleFit.
Rule 1 (support = 33.75%) Rule 6 (support = 8%)
24.5 (0), FPIR ,56.5 (0)
Early C-Peptide Response , 3.9 (0.67) Peak C-Peptide , 4.75 (0.85)
Timing of the Peak C-Peptide . 2.5 (0.12)
Rule 2 (support = 46.88%) Rule 7 (support = 57.19%)
ICA ,240 (0) IAA , 369.7 (3.84)
IAA , 369.7 (4.84) Fasting Glucose (IVGTT) , 103.5 (2.24)
Fasting Glucose (IVGTT) , 98.5 (1.72)
Rule 3 (support = 16.56%) Rule 8 (support = 32.81%)
Age , 13.89 (1.45) ICA . 120 (3.35)
BMI . 19.27 (1.37) AUC C-Peptide , 638.2 (3.61)
2 hr Glucose . 97.5 (4.08)
Rule 4 (support = 59.38%) Rule 9 (support = 40.94%)
Age , 18.24 (0) 2 hr Glucose , 117.5 (2.27)
2 hr Glucose . 87.5 (1.96) FPIR . 70.5 (1.13)
ICA . 30 (0)
Rule 5 (support = 66.25%) Rule 10 (support = 31.25%)
ICA . 30 (0) ICA . 60 (1.39)
FPIR , 155 (0) Early C-Peptide Response , 4.1 (0.67)
7.906 (1.04) , Age , 18.24 (0)
Note: the value in the bracket indicates the standard derivation that is calculated by the 80/20 cross validation as described in Section 3.4.
doi:10.1371/journal.pone.0091095.t002
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separate out underlying disease risk, identify progression types,
and pinpoint the progression stage. Using a unified framework of
RuleFit and latent trait theory, several risk-predictive rules are
identified, and its risk estimation performance is examined by cross
validation. The results in our study suggest that the ten rules in
Table 2, together with the latent trait theory that synthesizes the
information of these rules, provide a good risk estimation model.
The important risk factors that are significantly involved in the
ten rules in Table 2 are ICA, age, 2 hr glucose, IAA, FPIR, fasting
glucose, BMI, and some C-Peptide markers. Among them, ICA,
IAA, GAD, are autoantibodies, which have been found to be
associated with T1D in a number of studies in literature [2,6–
8,12,18]. Existing evidences also show that FPIR, C-Peptide
markers, 2 hr glucose, and fasting glucose are important in the
development of risk score models [12,6,7]. Age and BMI have also
been reported to be predictive of T1D in DPT-1 [6,7] and some
other cohorts [19]. Our results also show that gender is found to be
significantly interacting with the other variables included in our
study. This is consistent with previous findings that incidence
trends generally do not differ between genders [20].
In these derived rules by RuleFit, the cutoff points of the
markers in the rules are consistent with reported results in existing
Figure 2. Kaplan-Meier survival curves (with their 95% confidence intervals) of the two groups defined by each rule: one satisfies
the rule (dotted curve) and one doesn’t (solid curve).
doi:10.1371/journal.pone.0091095.g002
Table 3. P-values of the logrank test of the ten rules.
Rules P-value of the Logrank test Rules P-value of the Logrank test
Rule 1 0.0091 Rule 6 4.44e–15
Rule 2 1.98e–13 Rule 7 8.95e–10
Rule 3 2.36e–07 Rule 8 1.12e–12
Rule 4 3.5e–10 Rule 9 3.55e–11
Rule 5 1.13e–07 Rule 10 1.73e–09
doi:10.1371/journal.pone.0091095.t003
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studies. For example, the studies in [21,22] classified subjects into
three risk categories according to FPIR: low risk group if FPIR .
80–100 mU/L, intermediate risk group if 80 mU/L . FPIR .
65 mU/L, high risk group if FPIR , 65 mU/L. Similar results
were also shown by the study conducted by the Islet Cell Antibody
Registered Users Group in [21], which classified subjects into
three risk categories according to FPIR: low risk group if FPIR .
100 mU/L, intermediate risk group if 100 mU/L . FPIR .
50 mU/L, high risk group if FPIR , 50 mU/L. Our results are
similar with theirs: i.e., in Rule 6, FPIR , 56.5 mU/L is
considered as a sign of high risk which is close to the cutoff point,
65 mU/L; In Rule 9, FPIR . 70.5 mU/L is considered as low
risk, which is close to the cutoff point, 80–100 mU/L. The slight
differences between the cutoff points in our study with theirs may
be due to the fact that both Rule 6 and Rule 9 involve interactions
of FPIR with other markers.
The 2 hr glucose level is involved in Rules 4, 8, and 9. Among
these three rules, Rules 4 and 8 are risk-increasing rule, while Rule
9 is a risk-decreasing rule. According to 1999 WHO diabetes
criteria, the normal range of 2 hr glucose level is , 140 mg/dL,
the impaired glucose tolerance is .140 mg/dL, and the diabetes
mellitus is .200 mg/dL. The cutoff point in Rule 9 is consistent
with these criteria, as 2 hr glucose , 117.5 mg/dL is not
considered a risk by the 1999 WHO diabetes criteria as well. An
interesting discovery is that the cutoff points in Rules 4 and 8 are
87.5 mg/dL and 97.5 mg/dL, respectively, beyond which the
subject is predicted with increased risk. As 87.5 mg/dL or
97.5 mg/dL are within the normal range, our results indicate
that even the 2 hr glucose is in its normal range, it is still possible
that it will be indicative of T1D risk. A similar result was reported
(that was also conducted on DPT-1 cohort), which revealed to
reveal that the 2 hr glucose . 114 mg/dL is the optimal cutoff
point for classifying the progressor from nonprogressor. A few
studies [10] have shown that some markers within their
conventionally defined normal ranges may still be predictive of
disease risk. One explanation is that, in Rules 4 and 8, the 2 hr
glucose level is considered in conjunction with Age, ICA and C-
Peptide, i.e., ICA . 30 JDF Unit and ICA . 120 JDF Unit have
been derived in Rules 4 and 8, respectively. As ICA . 10 JDF
Unit is usually considered as evidence of risk, e.g., that was used in
DPT-1 protocol, a larger ICA value may push the normal range of
2 hr glucose to a smaller value than 140 mg/dL. Existing research
in literature has shown that the cutoff point of one marker may
depend on some other markers. For example, in [23], authors
stated that the cutoff point of HOMR-IR depends on BMI, i.e.,
HOMA-IR . 4.65 if BMI . 28.9 kg/m2, or HOMA-IR . 3.6 if
BMI . 27.5 kg/m2; both cut-offs are indicative of insulin
resistance.
The fasting glucose level derived from IVGTT is considered as
risk-decreasing in Rules 2 and 7, if IVGTT , 98.5 mg/dL and
IVGTT , 103.5 mg/dL, respectively. These cutoff points are
similar with existing studies [10], where IVGTT , 96 mg/dL was
definedwithin the normal range. However, the interpretation of
Rules 2 and 7 needs extra caution, since ICA , 240 is involved in
Rule 2 and IAA , 369.7 is involved in Rule 7. As ICA . 10 JDF
Unit and IAA . 80 nU/mL [4,5,24] (or IAA . 39 nU/mL [25])
are usually considered as evidence of risk, there seems a
contradiction. One explanation is that IVGTT , 98.5 mg/dL
and IVGTT , 103.5 mg/dL are risk-decreasing evidence, which
outweigh the risk-increasing evidence, ICA , 240 and IAA ,
369.7. As such, these two rules maybe only statistically meaningful.
The clinical underpinning of these two rules needs to be further
investigated, since the support of these two rules are as high as
46.88% and 57.19%, respectively, which indicates that a
considerable proportion of subjects in DPT-1 cohort express these
patterns.
The AUC C-Peptide and Peak values of C-Peptide are involved
in Rules 6 and 8. In our study, the observation that AUC C-
Peptide , 638.2 indicates risk is consistent with a previous study
on the DPT-1 cohort [10], which showed that AUC C-Peptide ,
595 indicated risk. The Peak value of C-Peptide , 4.75 is also
close to the reported result in [10], in which Peak value of C-
Peptide , 5.3. In addition, we also find that the timing of the Peak
C-Peptide and the early C-Peptide response are both important
risk factors. Particularly, as early C-Peptide response is related to
insulin secretion, the cutoff point used in Rule 1, as low as 3.9,
indicates loss of insulin secretion. Also, both Age and BMI are two
common risk factors in predicting T1D, such as the risk score
models in [6,7]. It is interesting to observe that these two risk
Figure 3. Item response functions of the 10 rules.
doi:10.1371/journal.pone.0091095.g003 Figure 4. Item information curves of the 10 rules.
doi:10.1371/journal.pone.0091095.g004
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factors form a single rule, Rule 3, without interacting with another
risk factor.
The latent trait theory has also revealed a considerable
heterogeneity of the relationships between the rules with the
underlying disease risk, indicating that the biological underpin-
nings of these rules maybe quite different. It successfully
distinguishes the risk-increasing rules from the risk-decreasing
rules, i.e., Rules 2, 7 and 9, which are consistent with the Kaplan-
Meier survival analysis as shown in Fig. 2. From Figs. 3 and 4, it
can be seen that the ten rules provide a pretty good coverage of the
middle part of the disease risk continuum, i.e., the moderate-risk
part, but less informative at higher levels of disease risk, and least
informative at lower levels of disease risk. This indicates that the
ten rules may lead to accurate risk estimation on the subjects that
have moderate-risk of developing T1D, with smaller statistical
error than the risk estimation of low-risk or high-risk group. If
more accurate estimation is needed for ascertaining how low or
how high the risk is, more rules that cover these two groups are
needed.
By utilizing the relationships between rules with the underlying
disease risk, the prediction results in Section 3.4 have demon-
strated that the latent trait theory is capable of providing accurate
assessment of disease risk. In summary, these results show that the
latent trait theory is a powerful model that can be used to identify
the roles of the rules, model the relationships between rules with
the underlying disease risk, and synthesize the rules for an overall
personalized risk estimation.
There are limitations of this study. First, note that the rules are
identified from the DPT-1 cohort. The conclusions are contingent
upon the presence of ICA, since ICA positivity is used as the
inclusion criteria in DPT-1. As such, further validation on some
other cohorts is needed to investigate to what extent the identified
rules and the corresponding risk estimation model can be applied
to other populations. Second, the rules and the corresponding risk
estimation model may not be fully applicable if the methodologies
for glucose and C-Peptide measurements are different from those
used in DPT-1. Third, the proposed statistical methodology can be
further improved to incorporate domain knowledge, since it is
developed on pure statistical considerations. Therefore, some rules
that are indeed predictive and clinically significant may be missed
since they will not add extra predictive capability to the existing
pool of rules. A more intelligent rule pruning method may be
developed. It is also of interest to develop more flexible latent trait
models, e.g., nonparametric latent trait models, which can allow us
to make more flexible assumptions about the item response
functions. Therefore, better prediction accuracy maybe obtained
from such nonparametric latent trait models.
As far as we know, our work is the first personalized risk model
that is ever developed for T1D, as existing risk scores models [6–8]
are only capable of stratifying subjects into different risk levels. By
identifying a comprehensive set of risk-predictive rules from data,
which act as a set of sensors dispersed over the whole course of
disease progression, the risk estimation can be performed by
looking into each individual’s profile of abnormalities. The unified
statistical framework we proposed has several advantages over
many existing risk score models. First, it can deal with the
heterogeneity of the T1D population. Second, it can deal with a
mix of nominal, ordinal, count or continuous variables; it can also
combine a mixture of variables of different biological nature
without interpretation difficulty, as rules can provide a clear
representation of complex data. Third, as rules are scale
independent, data do not need to be standardized. Fourth, the
rules can be associated with the underlying disease progression by
the latent variable model, leading to nice interpretation and new
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knowledge for clinical decision making that is not provided by
existing risk score models.
It may further increase the predictive capability if more markers
and clinical variables can be included in the model. Another
approach is extending it to longitudinal data to incorporate
predictive patterns based on the change of some markers over
time. While the results in this study seem promising, we do not
suggest this is the final model to be applied in clinical practice,
given that the underlying biological contents of the rules are not
delineated. It may also be of interest to evaluate the predictive
performance of this model on some surrogate end-points, such as
the appearance of autoantibodies. In conclusion, the unified
framework proposed in this study is shown to be a promising tool
to identify risk-predictive rules from baseline characteristic data,
while the prognostic values of the rules are demonstrated by both
survival analysis and latent trait theory. The identified rules,
together with the latent trait theory that synthesizes the
information of these rules, can be used to identify individuals at
risk and monitor T1D progression. Last but not least, although the
MCMC algorithm is efficient in our case since both the number of
variables and the sample size are not large, as it has been known
that the MCMC algorithm is usually computational demanding,
particularly on high-dimensional problems, we will explore
approaches for accelerating the MCMC algorithm on high-
dimensional problems in our future study.
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